Risks with Gadolinium

FDA announced that it is requiring a "black box" warning on gadolinium based contrast media stating that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, and a potentially fatal disease known as nephrogenic systemic fibrosis (NSF).